Express News | Sonnet Biotherapeutics - Il-18 Clinical Trials Have Shown That, Although It Is Well Tolerated, Il-18 Has Poor Efficacy in Treatment of Cancers
Express News | Sonnet Biotherapeutics- Il-18(Bpr) Was Linked to Sonnet's Proprietary Tumor Targeting F(H)AB Platform, With or Without Single-Chain Wild-Type Il-12
Express News | Sonnet Biotherapeutics Holdings Inc - Il-18(Bpr) and Il-12 Could Be Combined for Broad Applications in Oncology and Cell-Based Therapies
Express News | Sonnet Biotherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, Son-1411 and Son-1400, Each Containing a Variant Il-18 Domain
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target
Express News | Sonnet Biotherapeutics - Board Initiated Process to Explore and Review a Range of Strategic Alternatives Focused on Maximizing Stockholder Value
Express News | Sonnet Biotherapeutics Holdings Inc - Announces Review of Strategic Alternatives
Express News | Sonnet Biotherapeutics: Clinical Benefit Seen at 4 Months Post-Initiation of Dosing in 35% of Evaluable Patients (8/23) With Advanced Solid Tumors
Express News | Sonnet Biotherapeutics: Announces Updated Clinical Data for Son-1010 as Monotherapy/Combined With Anti-Pd-L1, With Increase in Dose-Escalation Target
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined With an Anti-PD-L1, Along With an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Express News | EF Hutton Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $7
Sonnet BioTherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 275.84% EF Hutton $11 → $7 Maintains Buy 02/15/2024 1510.74% Chardan Capital $75 → $30 Maintain
Express News | Sonnet Biotherapeutics Holdings Inc: Qtrly Shr $0.07
Sonnet BioTherapeutic | 10-Q: Quarterly report
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the c
Sonnet BioTherapeutics Files to Sell 5M Shares of Common Stock for Holders
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic
No Data